227 related articles for article (PubMed ID: 30363472)
21. Imaging of Substantia Nigra in Parkinson's Disease: A Narrative Review.
Feraco P; Gagliardo C; La Tona G; Bruno E; D'angelo C; Marrale M; Del Poggio A; Malaguti MC; Geraci L; Baschi R; Petralia B; Midiri M; Monastero R
Brain Sci; 2021 Jun; 11(6):. PubMed ID: 34207681
[TBL] [Abstract][Full Text] [Related]
22. Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases.
Cilento EM; Jin L; Stewart T; Shi M; Sheng L; Zhang J
J Neurochem; 2019 Nov; 151(4):397-416. PubMed ID: 30474862
[TBL] [Abstract][Full Text] [Related]
23. Quantitative Electroencephalography Characteristics for Parkinson's Disease: A Systematic Review.
Shirahige L; Berenguer-Rocha M; Mendonça S; Rocha S; Rodrigues MC; Monte-Silva K
J Parkinsons Dis; 2020; 10(2):455-470. PubMed ID: 32065804
[TBL] [Abstract][Full Text] [Related]
24. Blood-based biomarkers for Parkinson's disease.
Chahine LM; Stern MB; Chen-Plotkin A
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1(0 1):S99-103. PubMed ID: 24262199
[TBL] [Abstract][Full Text] [Related]
25. Diffusion tensor imaging of nigral degeneration in Parkinson's disease: A region-of-interest and voxel-based study at 3 T and systematic review with meta-analysis.
Schwarz ST; Abaei M; Gontu V; Morgan PS; Bajaj N; Auer DP
Neuroimage Clin; 2013; 3():481-8. PubMed ID: 24273730
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive metabolic profiling of Parkinson's disease by liquid chromatography-mass spectrometry.
Shao Y; Li T; Liu Z; Wang X; Xu X; Li S; Xu G; Le W
Mol Neurodegener; 2021 Jan; 16(1):4. PubMed ID: 33485385
[TBL] [Abstract][Full Text] [Related]
27. Advances in Biomarker Research in Parkinson's Disease.
Mehta SH; Adler CH
Curr Neurol Neurosci Rep; 2016 Jan; 16(1):7. PubMed ID: 26711276
[TBL] [Abstract][Full Text] [Related]
28. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
29. Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression.
Marek K; Jennings D; Tamagnan G; Seibyl J
Ann Neurol; 2008 Dec; 64 Suppl 2():S111-21. PubMed ID: 19127587
[TBL] [Abstract][Full Text] [Related]
30. Peripheral biomarkers of Parkinson's disease as early reporters of central neurodegeneration.
Fasano M; Alberio T; Lopiano L
Biomark Med; 2008 Oct; 2(5):465-78. PubMed ID: 20477424
[TBL] [Abstract][Full Text] [Related]
31. Biomarkers for cognitive dysfunction in Parkinson's disease.
Kalia LV
Parkinsonism Relat Disord; 2018 Jan; 46 Suppl 1():S19-S23. PubMed ID: 28781202
[TBL] [Abstract][Full Text] [Related]
32. The Systemic Synuclein Sampling Study: toward a biomarker for Parkinson's disease.
Visanji NP; Mollenhauer B; Beach TG; Adler CH; Coffey CS; Kopil CM; Dave KD; Foroud T; Chahine L; Jennings D;
Biomark Med; 2017 Apr; 11(4):359-368. PubMed ID: 28353371
[TBL] [Abstract][Full Text] [Related]
33. What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic?
Kim D; Paik JH; Shin DW; Kim HS; Park CS; Kang JH
Exp Neurobiol; 2014 Dec; 23(4):352-64. PubMed ID: 25548535
[TBL] [Abstract][Full Text] [Related]
34. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
[TBL] [Abstract][Full Text] [Related]
35. Circulating miRNAs as Diagnostic Biomarkers for Parkinson's Disease.
Roser AE; Caldi Gomes L; Schünemann J; Maass F; Lingor P
Front Neurosci; 2018; 12():625. PubMed ID: 30233304
[TBL] [Abstract][Full Text] [Related]
36. Tai Chi and Parkinson's disease (PD): A systematic overview of the scientific quality of the past systematic reviews.
Kedzior KK; Kaplan I
Complement Ther Med; 2019 Oct; 46():144-152. PubMed ID: 31519271
[TBL] [Abstract][Full Text] [Related]
37. Current Challenges Towards the Development of a Blood Test for Parkinson's Disease.
Santiago JA; Potashkin JA
Diagnostics (Basel); 2014 Oct; 4(4):153-64. PubMed ID: 26852683
[TBL] [Abstract][Full Text] [Related]
38. Proteomics in Parkinson's disease: An unbiased approach towards peripheral biomarkers and new therapies.
Alberio T; Fasano M
J Biotechnol; 2011 Dec; 156(4):325-37. PubMed ID: 21925549
[TBL] [Abstract][Full Text] [Related]
39. Longitudinal Progression Markers of Parkinson's Disease: Current View on Structural Imaging.
Yang J; Burciu RG; Vaillancourt DE
Curr Neurol Neurosci Rep; 2018 Oct; 18(12):83. PubMed ID: 30280267
[TBL] [Abstract][Full Text] [Related]
40. Biomarkers and the Role of α-Synuclein in Parkinson's Disease.
Du T; Wang L; Liu W; Zhu G; Chen Y; Zhang J
Front Aging Neurosci; 2021; 13():645996. PubMed ID: 33833675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
